Emerging Opportunities In Biotech | Gilead Sciences (GILD) | Sarepta Therapeutics (SRPT) | Synergy Pharmaceuticals (SGYP)

1960
Gilead Sciences Logo

Today is an absolutely horrible day for markets around the world. As the Greek debt crisis continues to spiral out of control, Chinese markets have moved into bearish trends with the US markets following behind. However, even on the worst days in the market, emerging opportunities can be found. With that said, here are a few stocks that I believe are great opportunities for those looking for gains!

Gilead Sciences Stock Declines Amid Greek Concerns

Gilead Sciences, Inc. (NASDAQ: GILD)

In my opinion, Gilead Sciences is one of the best stocks in biotech today with a very impressive story behind it. GILD has taken control of the HIV and HCV treatment markets; and while large competitors have tried to take their piece of the pie, none have proven to be nearly as successful as Gilead Sciences. However, because of competitors stepping in, investors haven’t been willing to push this stock too high. As a result, GILD now has a PE ratio below 10; meaning that it is incredibly undervalued and insinuating incredible upside potential. Now, thanks to the Greek debt crisis, GILD is declining in price today; opening the window of opportunity for anyone who wants to get involved. So, if you’re looking for an opportunity in biotech, GILD is definitely one to look at.

Sarepta Therapeutics Declines Even After Completing NDA Submission

Sarepta Therapeutics Inc (NASDAQ: SRPT)

In the world of biotech, we tend to see massive gains any time news comes out about an NDA, or New Drug Application. Today, Sarepta Therapeutics announced that it has completed the rolling submission of the New Drug Application to the US Food and Drug Administration for eteplirsen. However, investors haven’t responded in the way that we have come to expect to see. Instead of pushing SRPT up on the positive news, investors have pulled the stock down in fears that the Greek Debt Crisis will have a long standing affect on worldwide markets. With that said, when things start to even out and concerns over the European economy die down, I’m expecting to see incredibly bullish activity from SRPT. So, this is one to keep a close eye on.

Synergy Pharmaceuticals Also Faces Declines Amid Greek Concerns

Synergy Pharmaceuticals Inc (NASDAQ: SGYP)

Last week, I was expecting to see positive news from this stock as we moved into this week. The reality is that Synergy Pharmaceuticals saw sharp gains after releasing data from a study into plecanatide. However, it has been going through a bit of a correction since then. After the stock reached support on Friday, I expected to see a reversal today. However, with the Greek Debt Crisis looming closer and closer to the danger zone, that’s not what happened. Unfortunately, SGYP continues to decline. However, this can become a positive. With more declines, I’m expecting the positive news to be even sweeter. So, this is definitely one to watch because when it breaks out, it’s going to generate massive gains for those involved.

Do You Know Of Any Others?

Do you know of any other stocks that are generating great opportunities in biotech? If so, let us know in the comments below!

NO COMMENTS

LEAVE A REPLY